On Monday, June 22, 2026, Definium Therapeutics announced positive preliminary results from its Phase 3 study of LSD (DT120) for major depressive disorder (MDD). These are the first Phase 3 results for both the company and LSD.
The data was well received by the markets, and Definium's stock soared following the news. Its market capitalization now exceeds $5.5 billion.
Meanwhile, in 2024, LSD received «Breakthrough Therapy» designation for its effectiveness in treating generalized anxiety disorder with a single dose, following the presentation of Mindmed’s positive results for its LSD formulation (MM120). The FDA’s «Breakthrough Therapy» designation is granted to therapies that are more effective than any other treatment currently available on the market for that condition.
